Novel drug lengthens survival in men with refractory prostate cancer
Researchers reported that the odds of overall survival were 30% better with cabazitaxel than with mitoxantone. Median survival rose from 12.7 months with mitoxantron to 15.1 months with cabazitaxel.
According to the press release announcing the study, cabazitaxel is a new type of taxane chemotherapy chemically modified to overcome the resistance mechanism that eventually hampers other taxanes.
“The benefit shown in the trial is clearly in the range of FDA acceptability,” noted A. Oliver Sarton, MD, of Tulane Cancer Center in New Orleans. “This success in refractory prostate cancer is likely to quickly lead to trials in other tumor types.”